Genmab — November 2017
-
not sure if you saw Dara abstract 3888, where the researchers said : Based on this work, we are planning to open a multi-institutional early phase clinical trial for children and young adults with relapsed and refractory T-ALL. https://ash.confex.com/ash/2017/webprogram/Paper101472.html
-
Tossetimen er først lige afsluttet og november er først lige begyndt
-
Shorterne træder typisk først til, når der er lidt kød at komme efter
-
Tror os vi har ramt bunden og kan holde os over 1200 fra nu af.
-
"Currently, home administration of SC rituximab but also brentuximab vedotin, eculizumab and more recently daratumumab is part of our standard of care."
https://ash.confex.com/ash/2017/webprogram/Paper104029.html -
I guess it is only rituximab that is being administered as SC. The rest are IV admininstration
-
ADC SC administration is not on the table currently
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind